Join to access to all OVN content. Join for Free
The Great Resignation is Now The Great Hesitation
careers

The Great Resignation is Now The Great Hesitation


Share This Article


Over the last few years, the employment market has moved through dramatic swings. In 2021 and 2022, millions of professionals left their roles in what became known as The Great Resignation. Jobs were abundant, companies were aggressively hiring, and the perceived level of risk was low. If a new role did not work out, another company seemed ready with a similar or better offer. That season inspired fast movement because it felt safe to leap, reset, and repeat if needed.

Today a different pattern has emerged. People are still thinking about career change, but the pace has slowed. I call this shift The Great Hesitation. It is not fueled by complacency or lack of ambition. It is fueled by calculation. The career landscape feels more like the quiet middle game of a chess match than a free spin at a prize wheel. Professionals know that a wrong move can be costly, not just inconvenient. With fewer open roles, stricter hiring requirements, and more competition for each seat, there is less margin for error.

This caution is shaped by several forces. Headlines continue to highlight inflation, layoffs, funding pressure, consolidation, and reorganizations. Many fear being the newest hire during uncertain seasons. Memories of rapid exits during The Great Resignation, followed by disappointment or misalignment, have also left a lasting impression. Some of those moves worked beautifully, but others revealed that not e

very green pasture stays green. That experience turned curiosity into due diligence.

Remote and hybrid flexibility has become valuable and is now something people are reluctant to surrender, especially as many companies increase their in-office expectations. When a current role

Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
3 Things I wish I knew about being a MSL
Partner Avatar MSL Talk: Tom Caravela, Mitchell D’Rozario

3 Things I wish I knew about being a MSL

Article
Leadership Lab: How To Spot When Employees Are About To Walk Away
Partner Avatar Michael Pietrack

Leadership Lab: How To Spot When Employees Are About To Walk Away

Article
How to Know When to Make a Job Change
Partner Avatar Michael Pietrack

How to Know When to Make a Job Change

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Explore OVN